Orbofiban acetate

N/A

Report date: 2022/05/17 17:46:51
NME

Base Information

Drug NameOrbofiban acetate
Drug Alias Name醋酸奥波非班orbofiban奥波非班orbofibanumSC-57099B +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-IIb/beta-3 antagonists
TargetsIntegrin alpha-IIb/beta-3
Therapy Area/IndicationsMyocardial InfarctionAngina, Unstable
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncDaiichi Sankyo Co Ltd
Active IndicationsN/A
Inactive IndicationsMyocardial InfarctionAngina, Unstable

Other Information

ATC CodeN/A
Related LinksKEGG